Collections

Latest programs

• Optimizing Biomarker Assessment and Related Treatment Decision-Making for Patients with HR-Positive Metastatic Breast Cancer

• Key Presentations from the 2025 American Society of Hematology (ASH) Annual Meeting — Chronic Lymphocytic Leukemia

+25 more programs

Latest programs

• Understanding and Caring for Patients with Nonmelanoma Skin Cancers

• What Is Molecular Residual Disease Analysis and Why Is It Clinically Relevant in Colorectal Cancer?

+7 more programs

Latest programs

• Expert Second Opinion: Current and Future Roles of Immunotherapy and Targeted Therapy in the Management of Advanced Gastroesophageal Cancers

• Expert Second Opinion: Investigators Discuss the Optimal Management of HER2-Positive Gastrointestinal Cancers

Latest programs

• What Clinicians Want to Know: First-Line and Maintenance Therapy for Patients with ER-Positive HER2-Positive Metastatic Breast Cancer

• 

  Practical Perspectives on the Current and Future Management of Immune Thrombocytopenia — What Happened at ASH 2025?

+13 more programs

Latest programs

• ESMO Congress 2025 Review — Urothelial Bladder Cancer

• ESMO Congress 2025 Review — Prostate Cancer

+3 more programs

Latest programs

• 

  Cases from the Community: Investigators Discuss the Optimal Role of Endocrine-Based and Other Strategies in the Management of HR-Positive Breast Cancer

• Cases from the Community: Investigators Discuss the Optimal Management of HER2-Positive Breast Cancer